Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 4/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.57 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.57 |
| ▸ | ITGAL | P20701 | 4/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645413 | 0.99 | ERAP2 (0.60) | ERAP2ALOX15KDM4EMEN1LMNA | |
| SCHEMBL642931 | 0.99 | ERAP2 (0.60) | ERAP2ALOX15KDM4EMEN1LMNA | |
| SCHEMBL27780903 | 0.99 | ERAP2 (0.60) | ERAP2ALOX15KDM4EMEN1LMNA | |
| SCHEMBL643229 | 0.99 | ERAP2 (0.60) | ERAP2ALOX15KDM4EMEN1LMNA | |
| SCHEMBL644404 | 0.99 | ERAP2 (0.60) | ERAP2ALOX15KDM4EMEN1LMNA | |
| Lithium SCHEMBL731228 | 0.98 | ERAP2 (0.59) | ERAP2ALOX15KDM4EMEN1LMNA | |
| Calcium SCHEMBL730968 | 0.98 | ERAP2 (0.59) | ERAP2ALOX15KDM4EMEN1LMNA | |
| Potassium SCHEMBL729278 | 0.98 | ERAP2 (0.59) | ERAP2ALOX15KDM4EMEN1LMNA | |
| Magnesium SCHEMBL730627 | 0.98 | KDM4E (0.61) | ERAP2ALOX15KDM4EMEN1LMNA | |
| SCHEMBL645026 | 0.98 | ERAP2 (0.59) | ERAP2ALOX15KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | claimed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | claimed |
| EP-2121728-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | Apotex Technologies Inc. (CA) | 2009-11-25 | — | — | EP | claimed |
| WO-2008064465-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-05 | — | — | WO | claimed |
| US-20150225341-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | APOTEX TECHNOLOGIES INC. | 2015-08-13 | — | — | US | disclosed |
| US-8735602-B2 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2014-05-27 | — | — | US | disclosed |
| US-8507449-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-13 | — | — | US | disclosed |
| US-8476235-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-07-02 | — | — | US | disclosed |
| US-20130072692-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PREOCESSES FOR THEIR MANUFACTURE. | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-8138221-B2 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | APOTEX TECHNOLOIGES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-8119606-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | Apotex Technologies (CA) | 2012-02-21 | — | — | US | disclosed |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| EP-2121729-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | Apotex Technologies Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121728-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | Apotex Technologies Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074128-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008064465-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072692-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PREOCESSES FOR THEIR MANUFACTURE. | TPH1, TMSB10, TRPC1 | ERAP2 2646/4885ALOX15 3651/4885KDM4E 2875/4885 |
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ERAP2 2902/4885ALOX15 4347/4885KDM4E 815/4885 |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | TPH1, CACNA1G, CACNA1S | ERAP2 2328/4885ALOX15 3742/4885KDM4E 2406/4885 |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | DDC, AADAT, GLUL | ERAP2 2964/4885ALOX15 4611/4885KDM4E 1255/4885 |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ERAP2 2902/4885ALOX15 4347/4885KDM4E 815/4885 |
| US-20150225341-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | TMSB10, TMSB4X, TSLP | ERAP2 2521/4885ALOX15 4176/4885KDM4E 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.